This was unlike data analyzed from the PRISM high-throughput genotype-specific cancer vulnerabilities database (60), showing that cancer cell lines harboring hotspot mutations in PIK3CA were more sensitive to paxalisib compared with cancers expressing WT-PIK3CA (94 versus 771, respectively), particularly in breast and ovarian cancers. This evidence concerns the gene PIK3CA and ovarian carcinoma.